吸入曲前列尼尔对肺实质疾病相关肺动脉高压多重疾病进展事件的影响:INCREASE试验事后分析
INCREASE试验事后分析评估吸入曲前列尼尔对肺实质疾病相关肺动脉高压患者多重疾病进展事件的影响。吸入曲前列尼尔组疾病进展事件总数(147 vs 215,P=0.018)及多重进展事件患者比例(22% vs 36%,P=0.005)均显著低于安慰剂组,支持在疾病进展后继续使用吸入曲前列尼尔。
要点
- 吸入曲前列尼尔组疾病进展事件总数显著少于安慰剂组(147 vs 215,P=0.018)。
- 吸入曲前列尼尔组多重进展事件患者比例显著低于安慰剂组(22% vs 36%,P=0.005)。
- 各疾病进展组分(6分钟步行距离下降、肺病加重、FVC下降、心肺住院、死亡)事件数在吸入曲前列尼尔组均较低。
核心结论
- 吸入曲前列尼尔组在首次疾病进展事件后发生进一步进展事件的风险显著低于安慰剂组。
- 结果支持临床实践中在疾病进展发生后继续使用吸入曲前列尼尔。
研究设计与样本
- INCREASE试验的事后分析,纳入163例吸入曲前列尼尔组和163例安慰剂组患者。
- 疾病进展事件定义为6分钟步行距离下降≥15%、基础肺病加重、心肺住院、肺移植、FVC下降≥10%或死亡,观察期16周。
主要发现
- 吸入曲前列尼尔组疾病进展事件总数为147(89/163例,55%),安慰剂组为215(109/163例,67%),P=0.018。
- 吸入曲前列尼尔组多重进展事件患者为35例(22%),安慰剂组为58例(36%),P=0.005。
- 各组分事件数:6分钟步行距离下降45 vs 64,肺病加重48 vs 72,FVC下降19 vs 33,心肺住院23 vs 33,死亡10 vs 12。
关键数值与推荐
- 疾病进展事件定义包括6分钟步行距离下降≥15%、基础肺病加重、心肺住院、肺移植、FVC下降≥10%或死亡。
- 主要比较指标为疾病进展事件总数及多重进展事件患者比例。
临床怎么用
- 在肺实质疾病相关肺动脉高压患者中,吸入曲前列尼尔可减少疾病进展事件及多重进展事件。
- 临床实践中出现疾病进展事件后,可考虑继续使用吸入曲前列尼尔。
局限性
- 为16周研究的事后分析,非预设主要终点。
- 多重事件分析为探索性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The INCREASE study of inhaled treprostinil met its primary endpoint of change in 6-minute-walk distance at Week 16. In addition, there were significantly fewer clinical worsening events in patients receiving inhaled treprostinil. However, the incidence of multiple events in the same patient is unknown. Objectives: This post hoc analysis evaluated the effect of continued treatment with inhaled treprostinil on the frequency and impact of multiple disease progression events. Methods: Patients enrolled in INCREASE were analyzed for disease progression events, defined as at least 15% decline in 6-minute-walk distance, exacerbation of underlying lung disease, cardiopulmonary hospitalization, lung transplantation, at least 10% decline in forced vital capacity, or death during the duration of the 16-week study. Measurements and Main Results: In total, 147 disease progression events occurred in the inhaled treprostinil group (89/163 patients, 55%) compared with 215 events (109/163 patients, 67%) in the placebo group (P = 0.018). There was a lower incidence of each disease progression component in the inhaled treprostinil group: 6-minute-walk distance decline (45 vs. 64 events), lung disease exacerbation (48 vs. 72 events), FVC decline (19 vs. 33), cardiopulmonary hospitalization (23 vs. 33 events), and death (10 vs. 12). Fewer patients receiving inhaled treprostinil had multiple progression events compared with those receiving the placebo (35 vs. 58, 22% vs. 36%; P = 0.005). Conclusions: Patients who received inhaled treprostinil were significantly less likely to experience further disease progression events after an initial event compared with patients receiving placebo. These results support the continuation of inhaled treprostinil despite the occurrence of disease progression in clinical practice.
引用
- Nathan SD, Tapson VF, Elwing J, et al. Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. Am J Respir Crit Care Med. 2022. PMID: 34767495. doi:10.1164/rccm.202107-1766OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。